Jounce Therapeutics Stock Return On Equity
| JNCEDelisted Stock | USD 1.88 0.00 0.00% |
Jounce Therapeutics fundamentals help investors to digest information that contributes to Jounce Therapeutics' financial success or failures. It also enables traders to predict the movement of Jounce Stock. The fundamental analysis module provides a way to measure Jounce Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jounce Therapeutics stock.
Jounce |
Jounce Therapeutics Company Return On Equity Analysis
Jounce Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Jounce Therapeutics Return On Equity | -0.25 |
Most of Jounce Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jounce Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Jounce Therapeutics has a Return On Equity of -0.2503. This is 98.96% lower than that of the Biotechnology sector and 99.31% lower than that of the Health Care industry. The return on equity for all United States stocks is 19.26% lower than that of the firm.
Jounce Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jounce Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jounce Therapeutics could also be used in its relative valuation, which is a method of valuing Jounce Therapeutics by comparing valuation metrics of similar companies.Jounce Therapeutics is currently under evaluation in return on equity category among its peers.
Jounce Fundamentals
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.62) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | (82.09 M) | |||
| Shares Outstanding | 52.64 M | |||
| Shares Owned By Insiders | 15.99 % | |||
| Shares Owned By Institutions | 85.33 % | |||
| Number Of Shares Shorted | 2.02 M | |||
| Price To Earning | 10.76 X | |||
| Price To Book | 0.27 X | |||
| Price To Sales | 7.27 X | |||
| Revenue | 82 M | |||
| Gross Profit | 27.2 M | |||
| EBITDA | (50.16 M) | |||
| Net Income | (50.92 M) | |||
| Cash And Equivalents | 148.56 M | |||
| Cash Per Share | 2.87 X | |||
| Total Debt | 11.89 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 6.78 X | |||
| Book Value Per Share | 3.54 X | |||
| Cash Flow From Operations | (28.88 M) | |||
| Short Ratio | 0.48 X | |||
| Earnings Per Share | (0.96) X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 141 | |||
| Beta | 0.75 | |||
| Market Capitalization | 101.59 M | |||
| Total Asset | 212.55 M | |||
| Retained Earnings | (292.79 M) | |||
| Working Capital | 173.66 M | |||
| Current Asset | 103.95 M | |||
| Current Liabilities | 51.26 M | |||
| Z Score | 3.78 | |||
| Net Asset | 212.55 M |
About Jounce Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jounce Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jounce Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jounce Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Jounce Stock
If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |